By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ImmunoGen, Inc. 

128 Sidney Street

Cambridge  Massachusetts  02139-4239  U.S.A.
Phone: 617-995-2500 Fax: 617-995-2510


SEARCH JOBS




Collaborations

GlaxoSmithKline (North Carolina) 

Raven Biotechnologies, Inc.  Partnership for the discovery and development of therapeutic MAbs for the treatment of ovarian cancer.

Medarex, Inc.  Partnership for the discovery and development of therapeutic MAbs for the treatment of ovarian cancer.





Company News
ImmunoGen (IMGN) Reports Third Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update 4/29/2016 10:33:47 AM
ImmunoGen (IMGN) Taps Former Shire (SHPG) Exec as New CEO 4/26/2016 6:15:37 AM
ImmunoGen (IMGN) Announces Initiation Of Clinical Testing Of First-in-Class IMGN779 For Acute Myeloid Leukemia 4/18/2016 11:39:24 AM
ImmunoGen (IMGN) CEO to Retire, Successor to be Named Soon 4/5/2016 6:54:25 AM
ImmunoGen (IMGN) Announces Presentations At Upcoming AACR Annual Meeting 3/30/2016 8:26:19 AM
GlycoMimetics, Inc. (GLYC) Appoints ImmunoGen (IMGN) CEO Daniel Junius To Board Of Directors 3/21/2016 10:28:16 AM
ImmunoGen (IMGN) And Merck & Co. (MRK) Establish Collaboration For Clinical Evaluation Of Mirvetuximab Soravtansine In Combination With Keytruda (Pembrolizumab) For The Treatment Of Ovarian Cancer 2/4/2016 8:03:31 AM
ImmunoGen (IMGN) Reports Second Quarter Fiscal Year 2016 Financial Results And Provides Corporate Update 1/29/2016 8:37:24 AM
ImmunoGen (IMGN) Earns Milestone With Bayer (BAY)’s Initiation Of A Phase 2 Clinical Study Designed To Support Anetumab Ravtansine Registration 1/26/2016 10:41:50 AM
ImmunoGen (IMGN) Announces Conference Call To Discuss Its Second Quarter Fiscal Year 2016 Financial Results 1/20/2016 8:11:24 AM
12345678910...
//-->